Skip to main content

Table 4 Overall pathological complete response rates in the three treatment arms

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Response

TCL (n = 10)

TCH (n = 36)

TCHL (n = 33)

pCR (no invasive cancer in the breast or LNs)

2 (20%)

19 (52.8%)

17 (51.5%)

p = 0.0839 (TCL vs. TCH); 1.000 (TCH vs. TCHL); 0.1488 (TCL vs. TCHL)

  1. Abbreviations: LN Lymph node, pCR Pathological complete response, TCH Docetaxel, carboplatin, and trastuzumab, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib, TCL Docetaxel, carboplatin, lapatinib
  2. Overall pCR rates within each treatment arm following 6 cycles of neoadjuvant TCL, TCH or TCHL
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us